- Home
- IPHA vs ATOM Comparison
IPHA vs ATOM Comparison
Compare IPHA & ATOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- ATOM
- Stock Information
- Founded
- IPHA 1999
- ATOM 2001
- Country
- IPHA France
- ATOM United States
- Employees
- IPHA N/A
- ATOM N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- ATOM Semiconductors
- Sector
- IPHA Health Care
- ATOM Technology
- Exchange
- IPHA Nasdaq
- ATOM Nasdaq
- Market Cap
- IPHA 160.1M
- ATOM 155.4M
- IPO Year
- IPHA 2019
- ATOM 2016
- Fundamental
- Price
- IPHA $1.74
- ATOM $4.82
- Analyst Decision
- IPHA Strong Buy
- ATOM Strong Buy
- Analyst Count
- IPHA 1
- ATOM 1
- Target Price
- IPHA $11.00
- ATOM $7.00
- AVG Volume (30 Days)
- IPHA 11.2K
- ATOM 588.0K
- Earning Date
- IPHA 09-11-2025
- ATOM 07-29-2025
- Dividend Yield
- IPHA N/A
- ATOM N/A
- EPS Growth
- IPHA N/A
- ATOM N/A
- EPS
- IPHA N/A
- ATOM N/A
- Revenue
- IPHA $20,831,349.00
- ATOM $121,000.00
- Revenue This Year
- IPHA $209.83
- ATOM $202.22
- Revenue Next Year
- IPHA $83.15
- ATOM $1,225.00
- P/E Ratio
- IPHA N/A
- ATOM N/A
- Revenue Growth
- IPHA N/A
- ATOM N/A
- 52 Week Low
- IPHA $1.29
- ATOM $2.31
- 52 Week High
- IPHA $3.51
- ATOM $17.55
- Technical
- Relative Strength Index (RSI)
- IPHA 42.70
- ATOM 48.65
- Support Level
- IPHA $1.71
- ATOM $4.89
- Resistance Level
- IPHA $1.90
- ATOM $5.55
- Average True Range (ATR)
- IPHA 0.08
- ATOM 0.27
- MACD
- IPHA 0.00
- ATOM 0.05
- Stochastic Oscillator
- IPHA 47.62
- ATOM 73.90
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About ATOM Atomera Incorporated
Atomera Inc is engaged in the business of developing, commercializing, and licensing proprietary processes and technologies for the semiconductor industry. The company's technology, named Mears Silicon Technology, or MST, is a thin film of re-engineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the majority of widely used transistor types in the semiconductor industry. The mears silicon technology of the company can be used for applications like Analog, DRAM, logic and processors, and SRAM.